Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
Axcelis Technologies reports developments tied to its role as a supplier of ion implantation systems and process applications for semiconductor manufacturing. Company updates commonly cover quarterly results, demand trends across memory, power, compound semiconductor and mature-node markets, and the performance of its customer support and installed-base services business.
News also includes technical participation at semiconductor industry conferences, lifecycle support for Purion-based implant platforms, sustainability targets for greenhouse gas emissions, investor-conference activity and governance changes such as finance leadership transitions. The recurring business context centers on equipment used in integrated-circuit fabrication and aftermarket services including spare parts, upgrades, maintenance and training.
Axcelis Technologies (Nasdaq: ACLS) has announced the shipment of its Purion H200™ high current implanter to a second leading power device manufacturer. This shipment aims to support production ramp for silicon power devices and reflects Axcelis's growth strategy in the power device market. The Purion H200 is notable for its versatility, precision, and productivity, catering to a wide energy range from 5keV to 200keV. This system is designed to meet the unique needs of foundry and power device manufacturers, enhancing their ability to develop advanced material modification applications.
Axcelis Technologies (Nasdaq: ACLS), a key player in ion implantation solutions for the semiconductor industry, will participate in B. Riley Securities' Vision Day on January 28, 2021. The event features a fireside chat with Kevin Brewer, executive vice president and CFO, and Doug Lawson, executive vice president of corporate marketing and strategy, scheduled for 3:30 p.m. EST. A webcast replay will be available post-event. Founded over 40 years ago, Axcelis is dedicated to enhancing semiconductor manufacturing processes. For more information, visit www.axcelis.com.
Axcelis Technologies (Nasdaq: ACLS) updated its fourth quarter 2020 financial guidance, expecting revenue of approximately $120 million, exceeding previous guidance of $110 million. Gross margin is projected at 43%, improved from 41%, with earnings per share rising to $0.32 from $0.21. The company also announced a $100 million share repurchase program for 2021, indicating strong confidence in operational prospects. Upcoming financial results will be disclosed on February 10, 2021, with a conference call scheduled for February 11, 2021.
Axcelis Technologies (Nasdaq: ACLS) announced its participation in the 23rd Annual Needham Virtual Growth Conference from January 11-15, 2021. Key executives including President and CEO Mary Puma, CFO Kevin Brewer, and EVP Doug Lawson will engage in a fireside chat on January 13 at 11:30 a.m. EST. The event will include one-on-one meetings and a live webcast accessible on their website. Axcelis, based in Beverly, Mass., specializes in ion implantation solutions for the semiconductor industry, boasting over 40 years of experience.
Axcelis Technologies (Nasdaq: ACLS) will participate in the 12th Annual CEO Investor Summit on December 16, 2020. Key executives, including Mary Puma, Kevin Brewer, and Doug Lawson, will engage in a virtual format with investors and analysts. This event allows for up to six meetings per company, and a pre-recorded company overview will be available for viewing 24 hours prior. Registration is required by December 10, 2020 to ensure participation in this exclusive event.
Axcelis Technologies (NASDAQ: ACLS) will participate in the virtual D.A. Davidson Semicap, Laser and Optical Conference on December 15, 2020. The management team will hold one-on-one meetings throughout the event. With over 40 years of experience, Axcelis supplies innovative ion implantation solutions critical to the semiconductor industry's manufacturing process.
Axcelis Technologies (ACLS) reported third-quarter 2020 revenue of $110.4 million, down from $123 million in Q2 2020. Operating profit decreased to $13.9 million, while net income was $10.8 million or $0.32 per diluted share, compared to $13.3 million or $0.39 per diluted share in the previous quarter. Gross margin improved to 43.6%. Cash and equivalents rose to $212.7 million. For Q4, revenue is projected to be around $110 million with a 41% gross margin and earnings per share of $0.21.
Axcelis Technologies (Nasdaq: ACLS), based in Beverly, Mass., is set to participate in the Benchmark Technology Conference on November 12th, 2020. The conference will be conducted virtually, featuring one-on-one meetings hosted by Doug Lawson, the executive vice president of corporate marketing and strategy. Investors interested in attending can get more details and schedule meetings through the Benchmark website.
With over 40 years in the industry, Axcelis specializes in ion implantation solutions crucial for semiconductor manufacturing.
Axcelis Technologies announced the shipment of multiple Purion VXE and Purion EXE high energy systems to major CMOS image sensor manufacturers. These systems, part of the Purion high energy implanter series, support advanced applications in the growing IoT and mobile markets. Bill Bintz, Executive Vice President, emphasized the demand for these high energy implants, which offer precise doping profiles. This development further strengthens Axcelis' leadership position in the semiconductor industry, showcasing a robust product portfolio designed to meet customer needs.
Axcelis Technologies (ACLS) will announce its third quarter 2020 financial results on November 5, 2020, at 4:00 p.m. ET. Following the release, a conference call will be held on November 6, 2020, at 8:30 a.m. ET, accessible via audio webcast on Axcelis' investor page. Participants can ask questions by dialing 866.588.8911 (or 707.294.1561 internationally) with Conference ID: 1999553. Axcelis has been innovating in the semiconductor industry for over 40 years, focusing on ion implantation systems.